1. Home
  2. CHGG vs BDTX Comparison

CHGG vs BDTX Comparison

Compare CHGG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chegg Inc.

CHGG

Chegg Inc.

HOLD

Current Price

$0.57

Market Cap

63.6M

Sector

Real Estate

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$2.15

Market Cap

116.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHGG
BDTX
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.6M
116.8M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
CHGG
BDTX
Price
$0.57
$2.15
Analyst Decision
Sell
Buy
Analyst Count
2
6
Target Price
N/A
$10.20
AVG Volume (30 Days)
678.8K
592.3K
Earning Date
02-09-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
88.15
130.71
EPS
N/A
0.39
Revenue
$376,908,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.53
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$1.20
52 Week High
$1.89
$4.94

Technical Indicators

Market Signals
Indicator
CHGG
BDTX
Relative Strength Index (RSI) 37.60 42.73
Support Level $0.53 $1.93
Resistance Level $0.68 $2.86
Average True Range (ATR) 0.04 0.14
MACD 0.00 -0.00
Stochastic Oscillator 13.52 38.39

Price Performance

Historical Comparison
CHGG
BDTX

About CHGG Chegg Inc.

Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Chegg Skilling; and Academic Services, which derives maximum revenue. Geographically, it derives in United States and International.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Share on Social Networks: